NCT01503008撤回不适用
Proteus Sustained Behavior Change Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- Self-efficacy
研究概览
简要总结
The study will test whether the Proteus Sustained Behavior Change (SBC) System will help Type 2 diabetics feel more able to perform self-care activities, feel less distressed about diabetes, and reduce mean fasting blood glucose levels. The SBC system uses ingestible and wearable sensing devices and mobile phones to reinforce positive behaviors around medication usage, exercise and rest.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Self-reported diagnosis of Type 2 Diabetes Mellitus within the past 2-12 months
- •Hemoglobin A1c ≥7.5 and ≤11, obtained with the point-of-care HbA1c diagnostic device during the enrollment visit
- •Self-reported current use of metformin for Type 2 diabetes
- •Male or female ≥ 18
- •Outpatient
- •Self-reported capacity to perform "moderate" exercise, as specified by in the 2010 joint American College of Sports Medicine/American Diabetes Association guidelines
- •Designation of one caregiver to be involved in the study for its entire duration. A caregiver can be a relative, friend, or trained or untrained hired individual.
- •Self-reported mobile phone reception at home and/or at work
- •Willingness to adhere to study procedures, including troubleshooting of the Raisin System by a third-party if needed. The third party will be blinded to any personal subject identifiers.
- •Capacity to read and speak English proficiently, as judged by the investigator during the screening interview
- •Capacity to understand the instructions for the study, as judged by the investigator during the screening interview
排除标准
- •Self-reported treatment with metformin for less than 2 months at the time of screening
- •Self-reported adverse reaction to metformin (e.g., ongoing nausea, vomiting, bloating, diarrhea) or to other concomitant medications being administered at the time of screening
- •Self-reported use of injectable hypoglycemic agents, such as insulin, exenatide, liraglutide or pramlintide
- •Physical or medical condition that could prevent safe participation in moderate levels of physical activity, as surveyed by the Physical Activity Readiness Questionnaire (PAR-Q) and interpreted by the investigator
- •Inability to use a mobile phone (e.g., to find icons or to open and to read a SMS), or inability to operate the approved glucometer that will be provided for use in the study
- •Self-reported current (i.e., in the last 12 months) alcohol or drug abuse (including, but not limited, to use of marijuana)
- •Positive urine pregnancy test for women
- •Women of child bearing potential who are not using a medically accepted means of contraception. Accepted means of contraception include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy
- •Self-reported history of myocardial infarction within past 60 days
- •Self-reported history of cerebral vascular accident within past 60 days
- •Self-reported history of skin sensitivity to adhesive medical tape or metals
- •Self-reported history of acute or chronic dermatitis, excluding atopic dermatitis
- •Self-reported allergies that could preclude safe participation in the study
- •Current participation in another clinical study, or participation in a clinical study in the past 30 days during which an investigational device or drug was used
- •Any condition that, in the investigator's opinion, would preclude the subject's being able to meet all of the protocol requirements, or would compromise the subject's safety during participation in the study
- •Presence of cognitive impairment, as judged by the investigator during the screening interview
- •Inability to provide informed consent for any reason
研究组 & 干预措施
Sustained Behavior Change system support
Experimental
干预措施: Proteus Sustained Behavior Change system (Device)
Control
Active Comparator
干预措施: Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors) (Drug)
结局指标
主要结局
Self-efficacy
时间窗: 3 months
As measured by the 13-item self-efficacy expectancies and outcomes expectancies sub-scale of the Multidimensional Diabetes Questionnaire
次要结局
- Perceived effectiveness of caregiver support(3 months)
- Diabetes-related distress(3 months)
- At-home measurements of fasting glucose(1, 6, 12 weeks)
- In-clinic measurements of fasting glucose(0, 6, 12 weeks)
- Usability(3 months)
- Device-related and -unrelated adverse events(Up to 4 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Enhancing Adherence in Type 2 Diabetes: The ENHANCE StudyDiabetes Mellitus, Type 2Diabetic NephropathyNCT00222846University of Pittsburgh288
已完成
不适用
Study of Impact of Behavioral Intervention- Exercise, Nutrition, Education- on Body Mass Index (BMI)ObesityNCT00132132Steward St. Elizabeth's Medical Center of Boston, Inc.30
已完成
不适用
Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D)Type 1 DiabetesNCT05413239Joslin Diabetes Center217
已完成
不适用
Acceptance and Commitment Therapy Principles for Diabetes PreventionDiabetes type2DiabetesDiabetes Mellitus, Type 2PreDiabetesNCT05260983University of Oregon301
已完成
不适用
O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and KuwaitDiabetes Mellitus, Type 2NCT05716724Novo Nordisk A/S288